Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Next-generation Sequencing03:00

Next-generation Sequencing

92.1K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
92.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Cancer·2026

Related Experiment Video

Updated: Aug 18, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K

Sequencing therapy in relapsed DLBCL.

Christopher R Flowers1, Oreofe O Odejide2

  • 1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Hematology. American Society of Hematology. Education Program
|December 9, 2022
PubMed
Summary
This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) is a common cancer. While many are cured, some relapse, requiring salvage therapy like chemoimmunotherapy, high-dose chemotherapy, and stem cell transplant, or newer CAR T-cell therapies.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.3K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K

Related Experiment Videos

Last Updated: Aug 18, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.3K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 30% of all lymphoma diagnoses worldwide.
  • While current therapies achieve a 5-year survival rate of 50-60%, a significant proportion of patients (10-15%) are refractory to initial treatment, and an additional 20-30% relapse after achieving a complete response.
  • Outcomes vary significantly based on relapse timing, with late relapses (>2 years) potentially having better prognoses than early relapses or primary refractory disease.

Purpose of the Study:

  • To review current treatment strategies for relapsed DLBCL.
  • To highlight emerging therapies and their role in managing refractory or relapsed disease.
  • To emphasize the importance of goals-of-care communication in DLBCL management.

Main Methods:

  • Review of current standard-of-care treatments for relapsed DLBCL.
  • Discussion of novel therapeutic options including chimeric antigen receptor T-cell (CAR T) therapy.
  • Exploration of challenges in treatment access and patient eligibility for advanced therapies.

Main Results:

  • The standard of care for relapsed DLBCL in eligible patients involves salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT).
  • Chimeric antigen receptor T-cell (CAR T) therapy is emerging as a viable option, particularly in the second-line setting.
  • A spectrum of novel therapies is available for patients who are ineligible for, cannot access, or have failed ASCT and/or CAR T therapies.

Conclusions:

  • Despite advances, DLBCL remains a life-threatening malignancy requiring ongoing therapeutic innovation.
  • The integration of novel agents like CAR T-cells is expanding treatment options for relapsed and refractory DLBCL.
  • Effective goals-of-care communication and serious illness conversations are crucial for optimizing patient care and experience in DLBCL management.